VIR BIOTECHNOLOGY, INC. (VIR) News

VIR BIOTECHNOLOGY, INC. (VIR): $44.69

-1.30 (-2.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VIR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter VIR News Items

VIR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VIR News Highlights

  • VIR's 30 day story count now stands at 22.
  • Over the past 28 days, the trend for VIR's stories per day has been choppy and unclear. It has oscillated between 1 and 13.
  • The most mentioned tickers in articles about VIR are GSK, DECK and TGA.

Latest VIR News From Around the Web

Below are the latest news stories about Vir Biotechnology Inc that investors may wish to consider to help them evaluate VIR as an investment opportunity.

Vir Biotechnology (VIR) Presents at Global Healthcare Virtual Conference 2021 - Slideshow

The following slide deck was published by Vir Biotechnology, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 20, 2021

Vir Biotechnology Inc (VIR): Price Down $-1.19 (-2.4)% Over Past Day, Down $-1.16 (-2.36)% Over Past Hour

Wainwright 23rd annual global investment conference on monday, sept. 13, at 4:00 a.m. The post Vir Biotechnology Inc (VIR): Price Down $-1.19 (-2.4)% Over Past Day, Down $-1.16 (-2.36)% Over Past Hour appeared first on ETF Daily News .

ETF Daily News | September 8, 2021

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19 th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m. PT / 12:30 p.m. ET.

Intrado Digital Media | September 8, 2021

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m. PT / 12:30 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the pr

Yahoo | September 8, 2021

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23 rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET.

Intrado Digital Media | September 7, 2021

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days. The Co

Yahoo | September 7, 2021

Vir Biotech-GSK''s COVID-19 Treatment Wins Provisional Approval In Australia

The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc''s (NASDAQ: VIR ) for sotrovimab, a monoclonal antibody for COVID-19. The approval covers adults and adolescents who do not require initiation of … Full story available on Benzinga.com

Benzinga | August 23, 2021

Vir Biotechnology Reports Provisional Approval Of Sotrovimab In Australia

LONDON (dpa-AFX) - Vir Biotechnology, Inc. (VIR) said the Australian Therapeutic Goods Administration has granted provisional marketing authorization for sotrovimab, a monoclonal antibody for the

FinanzNachrichten | August 23, 2021

Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia

First monoclonal antibody authorized in Australia First monoclonal antibody authorized in Australia

Intrado Digital Media | August 23, 2021

Bullish: Analysts Just Made A Sizeable Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts

Celebrations may be in order for Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders, with the analysts delivering a...

Yahoo | August 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.612 seconds.